B cell receptor specific for norovirus GI.1 and GII.4 VP1 epitopes

The B cell receptor (BCR) specific for norovirus GI.1 and GII.4 VP1 epitopes is a membrane-bound immunoglobulin complex on B lymphocytes that mediates the recognition of the major capsid protein (VP1) of human noroviruses. This receptor is a critical target in vaccine development because it can recognize conserved epitopes shared between the prototype GI.1 (Norwalk virus) and the pandemic GII.4 genotypes. Activation of these BCRs by vaccine antigens, such as virus-like particles (VLPs), induces the production of broadly neutralizing antibodies that prevent infection by blocking viral attachment to host cell receptors, specifically histo-blood group antigens (HBGAs). Targeting these specific BCRs is essential for achieving broad-spectrum protection against the diverse and rapidly evolving strains of norovirus that cause widespread gastroenteritis. Therapeutic strategies focus on eliciting high-affinity BCR responses through multivalent vaccine formulations to overcome the challenges of viral antigenic drift and provide long-lasting immunity.

Other names

Norovirus GI.1/GII.4 VP1-specific BCRCross-reactive norovirus B cell receptorGI.1/GII.4 cross-reactive B cell receptorNorovirus VP1-specific B cell receptor

Vaccine antigens (VP1 virus-like particles) bind to and cross-link these specific B cell receptors, triggering a signaling cascade that leads to B cell activation, proliferation, and differentiation into antibody-secreting plasma cells. The resulting antibodies neutralize norovirus by blocking the interaction between the viral VP1 protein and host histo-blood group antigens (HBGAs).